Alison Armour
Corporate Officer/Principal bei Royal College of Physicians & Surgeons of Glasgow
Profil
Derzeit hat Alison A. Armour die Position des Senior Vice President-Research & Development bei Halozyme Therapeutics, Inc. inne. Dr. Armour ist außerdem Mitglied des Royal College of Physicians & Surgeons of Glasgow. Dr. Armour war zuvor Vice President-Oncology bei GlaxoSmithKline Plc, Vice President-Oncology bei der Novartis AG und Chief Medical Officer von Endocyte, Inc. (eine Tochtergesellschaft der Novartis AG) und Director-Global Medical Science bei AstraZeneca Plc. Alison A. Armour erhielt einen Bachelor-Abschluss, einen Master-Abschluss und einen Doktortitel von der University of Glasgow.
Aktive Positionen von Alison Armour
Unternehmen | Position | Beginn |
---|---|---|
Royal College of Physicians & Surgeons of Glasgow
Royal College of Physicians & Surgeons of Glasgow Other Consumer ServicesConsumer Services The Royal College of Physicians and Surgeons of Glasgow is a multidisciplinary organization that sets standards of care for the prevention and treatment of sickness and trauma in travelers. The British company has published a good practice guide for providing a travel health service, which defines the standards of care every practitioner should achieve in their practice of travel medicine for the health and safety of the international traveler. The organization offers a wide range of membership benefits and discounts on clinical and non-clinical skills courses, conferences, and e-learning. The private company also provides examinations and assessments across medical, surgical, and dental specialties to advance the profession and improve patient care through continuing professional development. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Alison Armour
Unternehmen | Position | Ende |
---|---|---|
HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2020 |
NOVARTIS AG | Corporate Officer/Principal | 01.07.2015 |
GSK PLC | Corporate Officer/Principal | 01.07.2015 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01.08.2011 |
ENDOCYTE, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Alison Armour
University of Glasgow | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ASTRAZENECA PLC | Health Technology |
HALOZYME THERAPEUTICS, INC. | Health Technology |
NOVARTIS AG | Health Technology |
GSK PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
Endocyte, Inc.
Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Royal College of Physicians & Surgeons of Glasgow
Royal College of Physicians & Surgeons of Glasgow Other Consumer ServicesConsumer Services The Royal College of Physicians and Surgeons of Glasgow is a multidisciplinary organization that sets standards of care for the prevention and treatment of sickness and trauma in travelers. The British company has published a good practice guide for providing a travel health service, which defines the standards of care every practitioner should achieve in their practice of travel medicine for the health and safety of the international traveler. The organization offers a wide range of membership benefits and discounts on clinical and non-clinical skills courses, conferences, and e-learning. The private company also provides examinations and assessments across medical, surgical, and dental specialties to advance the profession and improve patient care through continuing professional development. | Consumer Services |